🇺🇸 Nifedipine Extended-Release Tablets in United States

146 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Completed Suicide — 33 reports (22.6%)
  2. Drug Ineffective — 28 reports (19.18%)
  3. Blood Pressure Increased — 15 reports (10.27%)
  4. Cardiac Arrest — 11 reports (7.53%)
  5. Dizziness — 11 reports (7.53%)
  6. Headache — 11 reports (7.53%)
  7. Nausea — 11 reports (7.53%)
  8. Medication Residue Present — 10 reports (6.85%)
  9. Dyspnoea — 9 reports (6.16%)
  10. Exposure Via Ingestion — 7 reports (4.79%)

Source database →

Nifedipine Extended-Release Tablets in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Nifedipine Extended-Release Tablets approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Nifedipine Extended-Release Tablets in United States?

Duke University is the originator. The local marketing authorisation holder may differ — check the official source linked above.